|
1
|
Bordalo Tonucci L, Dos Santos KM, De Luces Fortes Ferreira CL, Ribeiro SM, De Oliveira LL and Martino HS: Gut microbiota and probiotics: Focus on diabetes mellitus. Crit Rev Food Sci Nutr. 57:2296–2309. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M and Nageshwar Reddy D: Role of the normal gut microbiota. World J Gastroenterol. 21:8787–8803. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Giambò F, Italia S, Teodoro M, Briguglio G, Furnari N, Catanoso R, Costa C and Fenga C: Influence of toxic metal exposure on the gut microbiota (Review). World Acad Sci J: Feb 2, 2021 (Epub ahead of print). doi: org/10.3892/wasj.2021.90.
|
|
4
|
Kalinkovich A and Livshits G: A cross talk between dysbiosis and gut-associated immune system governs the development of inflammatory arthropathies. Semin Arthritis Rheum. 49:474–484. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, Nielsen J and Bäckhed F: Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 498:99–103. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Bianchi F, Duque ALRF, Saad SMI and Sivieri K: Gut microbiome approaches to treat obesity in humans. Appl Microbiol Biotechnol. 103:1081–1094. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Battson ML, Lee DM, Weir TL and Gentile CL: The gut microbiota as a novel regulator of cardiovascular function and disease. J Nutr Biochem. 56:1–15. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, Neyrinck AM, Possemiers S, Van Holle A, François P, de Vos WM, et al: Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes. 60:2775–2786. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Brunkwall L and Orho-Melander M: The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: From current human evidence to future possibilities. Diabetologia. 60:943–951. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M, et al: Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 23:850–858. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Su B, Liu H, Li J, Sunli Y, Liu B, Liu D, Zhang P and Meng X: Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus. J Diabetes. 7:729–739. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhao L, Chen Y, Xia F, Abudukerimu B, Zhang W, Guo Y, Wang N and Lu Y: A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota. Front Endocrinol (Lausanne). 9(233)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Liao X, Song L, Zeng B, Liu B, Qiu Y, Qu H, Zheng Y, Long M, Zhou H, Wang Y, et al: Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis. EBioMedicine. 44:665–674. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Alberti KG and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 15:539–553. 1998.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rodriguez-Valera F, Martin-Cuadrado AB, Rodriguez-Brito B, Pasić L, Thingstad TF, Rohwer F and Mira A: Explaining microbial population genomics through phage predation. Nat Rev Microbiol. 7:828–836. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al: MetaHIT Consortium: A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 464:59–65. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhao L, Lou H, Peng Y, Chen S, Zhang Y and Li X: Comprehensive relationships between gut microbiome and faecal metabolome in individuals with type 2 diabetes and its complications. Endocrine. 66:526–537. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Roager HM, Vogt JK, Kristensen M, Hansen LBS, Ibrügger S, Mærkedahl RB, Bahl MI, Lind MV, Nielsen RL, Frøkiær H, et al: Whole grain-rich diet reduces body weight and systemic low-grade inflammation without inducing major changes of the gut microbiome: A randomised cross-over trial. Gut. 68:83–93. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH and Jakobsen M: Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 5(e9085)2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, et al: A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 490:55–60. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lambeth SM, Carson T, Lowe J, Ramaraj T, Leff JW, Luo L, Bell CJ and Shah VO: Composition, diversity and abundance of gut microbiome in prediabetes and type 2 diabetes. J Diabetes Obes. 2:1–7. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Huang Y, Li SC, Hu J, Ruan HB, Guo HM, Zhang HH, Wang X, Pei YF, Pan Y and Fang C: Gut microbiota profiling in Han Chinese with type 1 diabetes. Diabetes Res Clin Pract. 141:256–263. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ebrahimzadeh Leylabadlo H, Sanaie S, Sadeghpour Heravi F, Ahmadian Z and Ghotaslou R: From role of gut microbiota to microbial-based therapies in type 2-diabetes. Infect Genet Evol. 81(104268)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Dalile B, Vervliet B, Bergonzelli G, Verbeke K and Van Oudenhove L: Colon-delivered short-chain fatty acids attenuate the cortisol response to psychosocial stress in healthy men: A randomized, placebo-controlled trial. Neuropsychopharmacology. 45:2257–2266. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Macia L, Thorburn AN, Binge LC, Marino E, Rogers KE, Maslowski KM, Vieira AT, Kranich J and Mackay CR: Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases. Immunol Rev. 245:164–176. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Priyadarshini M, Villa SR, Fuller M, Wicksteed B, Mackay CR, Alquier T, Poitout V, Mancebo H, Mirmira RG, Gilchrist A, et al: An acetate-specific GPCR, FFAR2, regulates insulin secretion. Mol Endocrinol. 29:1055–1066. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ørgaard A, Jepsen SL and Holst JJ: Short-chain fatty acids and regulation of pancreatic endocrine secretion in mice. Islets. 11:103–111. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Everard A and Cani PD: Gut microbiota and GLP-1. Rev Endocr Metab Disord. 15:189–196. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, Fu H, Xue X, Lu C, Ma J, et al: Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 359:1151–1156. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sivamaruthi BS, Fern LA, Rashidah Pg Hj Ismail DS and Chaiyasut C: The influence of probiotics on bile acids in diseases and aging. Biomed Pharmacother. 128(110310)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wahlström A, Sayin SI, Marschall HU and Bäckhed F: Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24:41–50. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Higuchi S: The physiological importance of bile acid structure and composition on glucose homeostasis. Curr Diab Rep. 20(42)2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chávez-Talavera O, Tailleux A, Lefebvre P and Staels B: Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology. 152:1679–1694.e3. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Trabelsi MS, Daoudi M, Prawitt J, Ducastel S, Touche V, Sayin SI, Perino A, Brighton CA, Sebti Y, Kluza J, et al: Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun. 6(7629)2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, et al: TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10:167–177. 2009.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Rajani C and Jia W: Bile acids and their effects on diabetes. Front Med. 12:608–623. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
González-Regueiro JA, Moreno-Castañeda L, Uribe M and Chávez-Tapia NC: The role of bile acids in glucose metabolism and their relation with diabetes. Ann Hepatol. 16 (Suppl 1: s3-105):16–21. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Hansen M, Sonne DP, Mikkelsen KH, Gluud LL, Vilsbøll T and Knop FK: Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials. J Diabetes Complications. 31:918–927. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R and Matthews DR: Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 38:140–149. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Sansome DJ, Xie C, Veedfald S, Horowitz M, Rayner CK and Wu T: Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids. Diabetes Obes Metab. 22:141–148. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Qiu Y, Shen L, Fu L, Yang J, Cui C, Li T, Li X, Fu C, Gao X, Wang W, et al: The glucose-lowering effects of α-glucosidase inhibitor require a bile acid signal in mice. Diabetologia. 63:1002–1016. 2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Gu Y, Wang X, Li J, Zhang Y, Zhong H, Liu R, Zhang D, Feng Q, Xie X, Hong J, et al: Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nat Commun. 8(1785)2017.PubMed/NCBI View Article : Google Scholar
|
